Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation

References

• Lee WM. Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol. 2012;26(1):3–16.
   PubMed Web of Science ®Google Scholar
• Issa AM, Philips KA, Van Bebber S, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007;2(3):177–185.
   PubMedGoogle Scholar
• Solotke MT, Dhruva SS, Downing NS, et al. New and incremental FDA black box warnings from 2008 to 2015. Expert Opin Drug Saf. 2018;17(2):117–123.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.
   PubMed Web of Science ®Google Scholar
• Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology. 2008;47(6):1813–1815.
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther. 2012;92(3):376–380.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29(4):383–392.
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Prediction of a new drug’s potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel. 2001;4(1):55–59.
   PubMedGoogle Scholar
• Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol. 2005;35(4):325–361.
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003–2009.
   PubMed Web of Science ®Google Scholar
• Lammert C, Björnsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615–620.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–396.
   PubMed Web of Science ®Google Scholar
• Cho T, Uetrecht J. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol. 2017;30(1):295–314.
   PubMed Web of Science ®Google Scholar
• Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503–514.
   PubMed Web of Science ®Google Scholar
• McGill MR, Yan HM, Ramachandran A, et al. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology. 2011;53(3):974–982.
   PubMed Web of Science ®Google Scholar
• McGill MR, Lebofsky M, Norris HR, et al. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications. Toxicol Appl Pharmacol. 2013;269(3):240–249.
   PubMed Web of Science ®Google Scholar
• Xie Y, McGill MR, Dorko K, et al. Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. Toxicol Appl Pharmacol. 2014;279(3):266–274.
   PubMed Web of Science ®Google Scholar
• Dart RC, Erdman AR, Olson KR, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2006;44(1):1–18.
   Web of Science ®Google Scholar
• James LP, Capparelli EV, Simpson PM, et al. Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther. 2008;84(6):684–690.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93.
   PubMed Web of Science ®Google Scholar
• Kuffner EK, Temple AR, Cooper KM, et al. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Curr Med Res Opin. 2006;22(11):2137–2148.
   PubMed Web of Science ®Google Scholar
• Dart RC, Bailey E. Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy. 2007;27(9):1219–1230.
   PubMed Web of Science ®Google Scholar
• Heard K, Green JL, Anderson V, et al. A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration. BMC Pharmacol Toxicol. 2014;15:39.
   PubMed Web of Science ®Google Scholar
• Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med. 2001;161(18):2247–2252.
   PubMed Web of Science ®Google Scholar
• Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther. 2007;26(2):283–290.
   PubMed Web of Science ®Google Scholar
• Bartels S, Sivilotti M, Crosby D, et al. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. Clin Toxicol. 2008;46(3):243–249.
   Web of Science ®Google Scholar
• Rumack B, Heard K, Green J, et al. Effect of therapeutic doses of acetaminophen (up to 4 g/day) on serum alanine aminotransferase levels in subjects consuming ethanol: systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy. 2012;32(9):784–791.
   PubMed Web of Science ®Google Scholar
• Nourjah P, Ahmad SR, Karwoski C, et al. Estimates of acetaminophen (paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15(6):398–405.
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of acetaminophen-containing products. Am J Prev Med. 2011;40(6):585–592.
   Google Scholar
• Manthripragada AD, Zhou EH, Budnitz DS, et al. Characterization of acetaminophen overdose-related emergency department visits and hospitalizations in the United States. Pharmacolepidemiol Drug Saf. 2011;20(8):819–826.
   PubMed Web of Science ®Google Scholar
• Major JM, Zhou EH, Wong HL, et al. Trends in rates of acetaminophen-related adverse events in the United States. Pharmacolepidemiol Drug Saf. 2016;25(5):590–598.
   PubMed Web of Science ®Google Scholar
• Lee WM. Etiologies of acute liver failure. Semin Liver Dis. 2008;28(2):142–152.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Ellerbe C, Schilsky M, et al. Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl. 2016;22(4):505–515.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. Acetaminophen (APAP or N-acetyl-p-aminophenol) and acute liver failure. Clin Liver Dis. 2018;22(2):325–346.
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res. 2013;30(9):2174–2187.
   PubMed Web of Science ®Google Scholar
• McGill MR, Williams CD, Xie Y, et al. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol. 2012;264(3):387–394.
   PubMed Web of Science ®Google Scholar
• Xie Y, McGill MR, Du K, et al. Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes. Toxicol Appl Pharmacol. 2015;289(2):213–222.
   PubMed Web of Science ®Google Scholar
• Han D, Shinohara M, Ybanez MD, et al. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol. 2010;196:267–310.
   PubMedGoogle Scholar
• Sharma M, Gadang V, Jaeschke A. Critical role for mixed-lineage kinase 3 in acetaminophen-induced hepatotoxicity. Mol Pharmacol. 2012;82(5):1001–1007.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, McGill MR, Xie Y, et al. Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice. Hepatology. 2013;58(6):2099–2108.
   PubMed Web of Science ®Google Scholar
• Du K, Xie Y, McGill MR, et al. Pathophysiological significance of c-Jun N-terminal kinase in acetaminophen hepatotoxicity. Expert Opin Drug Metab Toxicol. 2015;11(11):1769–1779.
   PubMed Web of Science ®Google Scholar
• Kon K, Kim JS, Jaeschke H, et al. Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. Hepatology. 2004;40(5):1170–1179.
   PubMed Web of Science ®Google Scholar
• LoGuidice A, Boelsterli UA. Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin D-regulated permeability transition. Hepatology. 2011;54(3):969–978.
   PubMed Web of Science ®Google Scholar
• Hu J, Ramshesh VK, McGill MR, et al. Low dose acetaminophen induces reversible mitochondrial dysfunction associated with transient c-Jun N-terminal kinase activation in mouse liver. Toxicol Sci. 2016;150(1):2014–2015.
   Web of Science ®Google Scholar
• Bajt ML, Cover C, Lemasters JJ, et al. Nuclear translocation of endonuclease G and apoptosis-inducing factor during acetaminophen-induced liver cell injury. Toxicol Sci. 2006;94(1):217–225.
   PubMed Web of Science ®Google Scholar
• Bajt ML, Ramachandran A, Yan HM, et al. Apoptosis-induced factor modulates mitochondrial oxidant stress in acetaminophen hepatotoxicity. Toxicol Sci. 2011;122(2):598–605.
   PubMed Web of Science ®Google Scholar
• Gujral JS, Knight TR, Farhood A, et al. Mode of cell death after acetaminophen overdose in mice: apoptosis or oncotic necrosis? Toxicol Sci. 2002;67(2):322–328.
   PubMed Web of Science ®Google Scholar
• Muldrew KL, James LP, Coop L, et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos. 2002;30(4):446–451.
   PubMed Web of Science ®Google Scholar
• Davern TJ 2nd, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology. 2006;130(3):687–694.
   PubMed Web of Science ®Google Scholar
• McGill MR, Sharpe MR, Williams CD, et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest. 2012;122(4):1574–1583.
   PubMed Web of Science ®Google Scholar
• McGill MR, Staggs VS, Sharpe MR, et al. Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outcome. Hepatology. 2014;60(4):1336–1345.
   PubMed Web of Science ®Google Scholar
• Massart J, Begriche K, Moreau C, et al. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212–232.
   PubMedGoogle Scholar
• Vitcheva V. Cocaine toxicity and hepatic oxidative stress. Curr Med Chem. 2012;19(33):5677–5682.
   PubMed Web of Science ®Google Scholar
• Banerjee AK, Lakhani S, Vincent M, et al. Dose-dependent acute hepatitis associated with administration of high dose methotrexate. Hum Toxicol. 1988;7(6):561–562.
   PubMedGoogle Scholar
• Grecian R, Ainslie M. Acute hepatic failure following intravenous amiodarone. BMJ Case Rep 2012; pii.bcr2012007080.
   PubMedGoogle Scholar
• Chen CC, Wu CC. Acute hepatotoxicity of intravenous amiodarone: case reports and review of the literature. Am J Ther. 2016;23(1):e260–e263.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015 Jun;148(7):1340–1352.
   PubMed Web of Science ®Google Scholar
• Vega M, Verma M, Beswick D, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf. 2017;40(9):787.
   Web of Science ®Google Scholar
• Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53(2):182–189.
   PubMed Web of Science ®Google Scholar
• Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65(3):532–542.
   PubMed Web of Science ®Google Scholar
• Mosedale M, Watkins PB. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469–480.
   PubMed Web of Science ®Google Scholar
• Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases. Gut. 1997;41(4):534–540.
   PubMed Web of Science ®Google Scholar
• Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology. 2013;57(2):727–739.
   Google Scholar
• Heard K, Green JL, Anderson V, et al. Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. Br J Clin Pharmacol. 2016;81(3):562–568.
   PubMed Web of Science ®Google Scholar
• Heard KJ, Green JL, James LP, et al. Acetaminophen-cysteine adducts during therapeutic dosing and following overdose. BMC Gastroenterol. 2011;11:20.
   PubMed Web of Science ®Google Scholar
• White KD, Chung WH, Hung SI, et al. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response. J Allergy Clin Immunol. 2015;136(2):219–234.
   PubMed Web of Science ®Google Scholar
• Ong MM, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci. 2007;97(1):205–213.
   PubMed Web of Science ®Google Scholar
• Lee KK, Fujimoto K, Zhang C, et al. Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes. Free Radic Biol Med. 2013;65:584–594.
   PubMed Web of Science ®Google Scholar
• Li J, Uetrecht JP. The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol. 2010;196:493–509.
   PubMedGoogle Scholar
• Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777–787.
   PubMed Web of Science ®Google Scholar
• Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3(2):104–113.
   PubMed Web of Science ®Google Scholar
• Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2018. Epub ahead of print. doi:10.1002/hep.29802
   Google Scholar
• Nelson RL, Povey MS, Hopkinson DA, et al. Electrophoresis of human l-glutamate dehydrogenase: tissue distribution and preliminary population survey. Biochem Genet. 1977;15(1–2):87–91.
   PubMed Web of Science ®Google Scholar
• Racine-Samson L, Scoazec JY, D’Errico A, et al. The metabolic organization of the adult human liver: a comparative study of normal, fibrotic, and cirrhotic liver tissue. Hepatology. 1996;24(1):104–113.
   PubMed Web of Science ®Google Scholar
• Schmidt ES, Schmidt FW. Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme. Clin Chim Acta. 1988;173(1):43–55.
   PubMed Web of Science ®Google Scholar
• Weemhoff JL, Woolbright BL, Jenkins RE, et al. Plasma biomarkers to study mechanisms of liver injury in patients with hypoxic hepatitis. Liver Int. 2017;37(3):377–384.
   PubMed Web of Science ®Google Scholar
• Schomaker S, Warner R, Bock J, et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci. 2013;132(2):276–283.
   PubMed Web of Science ®Google Scholar
• Marques PE, Amaral SS, Pires DA, et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology. 2012;56(5):1971–1982.
   PubMed Web of Science ®Google Scholar
• He Y, Feng D, Li M, et al. Hepatic mitochondrial DNA/toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation acetaminophen hepatotoxicity in mice. Hepatology. 2017;66(1):220–234.
   PubMed Web of Science ®Google Scholar
• McGill MR, Li F, Sharpe MR, et al. Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Arch Toxicol. 2014b;88(2):391–401.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Yan K, Pence L, et al. Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomark Med. 2014;8(2):147–159.
   PubMed Web of Science ®Google Scholar
• Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology. 2010 Jan;51(1):246–254.
   PubMed Web of Science ®Google Scholar
• Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005;15(5):496–506.
   PubMed Web of Science ®Google Scholar
• Venereau E, De Leo F, Mezzapelle R, et al. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534–544.
   PubMed Web of Science ®Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22(20):5551–5560.
   PubMed Web of Science ®Google Scholar
• Yang H, Antoine DJ, Andersson U, et al. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013;93(6):865–873.
   PubMed Web of Science ®Google Scholar
• Dhupar R, Klune JR, Evankovich J, et al. Interferon regulatory factor 1 mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver ischemia-reperfusion injury. Shock. 2011;35(3):293–301.
   PubMed Web of Science ®Google Scholar
• Leers MP, Kögen W, Björklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999;187(5):567–572.
   PubMed Web of Science ®Google Scholar
• Woolbright BL, Bridges BW, Dunn W, et al. Cell death and prognosis of mortality in alcoholic hepatitis patients using Plasma Keratin-18. Gene Expr. 2017;17(4):301–312.
   PubMedGoogle Scholar
• Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 2009;106(11):4402–4407.
   PubMed Web of Science ®Google Scholar
• Starkey-Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(4):1767–1776.
   PubMedGoogle Scholar
• Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci USA. 2014;111(33):12169–12174.
   PubMed Web of Science ®Google Scholar
• Krauskopf J, Caiment F, Claessen SM, et al. Application of high-throughput sequencing to circulating microRNAs reveals novel biomarkers for drug-induced liver injury. Toxicol Sci. 2015;143(2):268–276.
   PubMed Web of Science ®Google Scholar
• Yang X, Salminen WF, Shi Q, et al. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol Appl Pharmacol. 2015;284(2):180–187.
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. MicroRNAs as signaling mediators and biomarkers of drug- and chemical-induced liver injury. J Clin Med. 2015;4(5):1063–1078.
   PubMed Web of Science ®Google Scholar
• Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017;37(5):757–764.
   PubMed Web of Science ®Google Scholar
• Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56(6):1946–1957.
   PubMedGoogle Scholar
• Qi R, Weiland M, Gao XH, et al. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology. 2012;55(5):1640–1642.
   PubMed Web of Science ®Google Scholar
• Vliegenthart ADB, Berends C, Potter CMJ, et al. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol. 2017;83(9):2027–2033.
   PubMed Web of Science ®Google Scholar
• Rissin DM, Lópex-Longarele B, Pernagallo S, et al. Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: detection of drug-induced liver injury. PLoS One. 2017;12(7):e0179669.
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Miyake M, Sato H, et al. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol. 2013;268(1):79–89.
   PubMed Web of Science ®Google Scholar
• Woolbright BL, McGill MR, Staggs VS, et al. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci. 2014;142(2):436–444.
   PubMed Web of Science ®Google Scholar
• Luo L, Schomarker S, Houle C, et al. Evalutation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci. 2014;137(1):12–25.
   PubMed Web of Science ®Google Scholar
• James L, Yan K, Pence L, et al. Comparison of bile acids and acetaminophen protein adducts in children and adolescents with acetaminophen toxicity. PLoS One. 2015;10(7):e0131010.
   PubMed Web of Science ®Google Scholar
• Slopianka M, Herrmann A, Pavkovic M, et al. Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats. Toxicology. 2017;386:1–10.
   PubMed Web of Science ®Google Scholar
• Luo L, Aubrecht J, Li D, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS One. 2018;13(3):e0193824.
   PubMed Web of Science ®Google Scholar
• Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology. 2005;41(1):26–31.
   PubMed Web of Science ®Google Scholar
• Schiødt FV, Ostapowicz G, Murray N, et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl. 2006;12(12):1776–1781.
   PubMed Web of Science ®Google Scholar
• Sato Y, Watanabe H, Kameyama H, et al. Changes in serum LECT 2 levels during the early period of liver regeneration after adult living related donor liver transplantation. Transplant Proc. 2004;36(8):2357–2358.
   PubMed Web of Science ®Google Scholar
• Sato Y, Watanabe H, Kameyama H, et al. Serum LECT2 level as a prognostic indicator in acute liver failure. Transplant Proc. 2004;36(8):2359–2361.
   PubMed Web of Science ®Google Scholar
• Wen Y, Feng D, Wu H, et al. Defective initiation of liver regeneration in osteopontin-deficient mice after partial hepatectomy due to insufficient activation of IL-6/Stat3 pathway. Int J Biol Sci. 2015;11(10):1236–1247.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhao C, Chen S, et al. A preliminary in vivo study of the effects of OPN on rat liver regeneration induced by partial hepatectomy. Mol Biol Rep. 2016;43(12):1371–1382.
   PubMed Web of Science ®Google Scholar
• Arai M, Yokosuka O, Kanda T, et al. Serum osteopontin levels in patients with acute liver dysfunction. Scand J Gastroenterol. 2006;41(1):102–110.
   PubMed Web of Science ®Google Scholar
• Lutkewitte AJ, Schweitzer GG, Kennon-McGill S, et al. Lipin deactivation after acetaminophen overdose causes phosphatidic acid accumulation in liver and plasma in mice and humans and enhances liver regeneration. Food Chem Toxicol. 2018;115:273–283.
   PubMed Web of Science ®Google Scholar
• McGill MR, Cao M, Svetlov A, et al. Argininosuccinate synthetase as a plasma biomarker of liver injury after acetaminophen overdose in rodents and humans. Biomarkers. 2014;19(3):222–230.
   PubMed Web of Science ®Google Scholar
• Beckett GJ, Chapman BJ, Dyson EH, et al. Plasma glutathione S-transferase measurements after paracetamol overdose: evidence for early hepatocellular damage. Gut. 1985;26(1):26–31.
   PubMed Web of Science ®Google Scholar
• Beckett GJ, Foster GR, Hussey AJ, et al. Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem. 1989;35(11):2186–2189.
   PubMed Web of Science ®Google Scholar
• Mikus M, Drobin K, Gry M, et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver Int. 2017;37(1):132–140.
   PubMed Web of Science ®Google Scholar
• Andersson U, Lindberg J, Wang S, et al. A systems biology approach to understanding elevated serum alanine aminotransferase levels in a clinical trial with ximelagatran. Biomarkers. 2009;14(8):572–586.
   PubMed Web of Science ®Google Scholar
• Qin S, Zhou Y, Gray L, et al. Identification of organ-enriched protein biomarkers of acute liver injury by targeted quantitative proteomics of blood in acetaminophen- and carbon-tetrachloride-treated mouse models and acetaminophen overdose patients. J Proteome Res. 2016;15(1):3724–3740.
   PubMedGoogle Scholar
• Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis. 2014;34(2):123–133.
   PubMed Web of Science ®Google Scholar
• Nyfors A, Svejgaard A. The relation of HL-A antigens to liver histology in methotrexate-treated psoriatics. Acta Derm Venereol. 1976;56(3):235–238.
   PubMed Web of Science ®Google Scholar
• Eade OE, Krawitt EL, Grice D, et al. HLA antigens and halothane hepatitis. Lancet. 1978;2(8104–5):1384–1385.
   PubMed Web of Science ®Google Scholar
• Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8(3):599–606.
   PubMed Web of Science ®Google Scholar
• Berson A, Fréneaux E, Larrey D, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol. 1994;20(3):336–342.
   PubMed Web of Science ®Google Scholar
• Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117(5):1181–1186.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transciptase inhibitor abacavir. Lancet. 2002;359(9308):727–732.
   PubMed Web of Science ®Google Scholar
• Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008;8(1):29–33.
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816–819.
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Daly AK, Henderson J, et al. Human leukocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53(6):1049–1053.
   PubMed Web of Science ®Google Scholar
• Singer JB, Lewitzky S, Leroy E, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–714.
   PubMed Web of Science ®Google Scholar
• Spraggs CF, Parham LR, Hunt CM, et al. Lapatinib-induced liver injury characterized by class II HLA and Gilbert’s syndrome genotypes. Clin Pharmacol Ther. 2012;91(4):647–652.
   PubMed Web of Science ®Google Scholar
• Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–347.
   PubMed Web of Science ®Google Scholar
• Phillips EJ, Sa M. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. AIDS. 2013;27(3):491–492.
   PubMed Web of Science ®Google Scholar
• Xu CF, Johnson T, Wang X, et al. HLA-B*5701 confers susceptibility to pazopanib-associated liver injury in patients with cancer. Clin Cancer Res. 2016;22(6):1371–1377.
   PubMed Web of Science ®Google Scholar
• Urban TJ, Nicoletti P, Chalasani N, et al. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B*35:02 as a risk factor. J Hepatol. 2017;67(1):137–144.
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Aithal GP, Bjornsson ES, et al. Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–1089.
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Werk A, Sawle A, et al. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupertine-induced liver injury. Pharmacogenet Genomics. 2016;26(5):218–224.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Eng J Med. 2008;358(6):568–579.
   PubMed Web of Science ®Google Scholar
• Court MH, Peter I, Hazarika S, et al. Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metab Dispos. 2014;42(1):28–32.
   PubMed Web of Science ®Google Scholar
• Court MH, Zhu Z, Masse G, et al. Race, gender and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American Volunteers. J Pharmacol Exp Ther. 2017;362(3):431–440.
   PubMed Web of Science ®Google Scholar
• Köhle C, Möhrle B, Münzel PA, et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol. 2003;65(9):1521–1527.
   PubMed Web of Science ®Google Scholar
• Xie Y, McGill MR, Cook SF, et al. Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells. Xenobiotica. 2015;45(10):921–929.
   PubMed Web of Science ®Google Scholar
• Esteban A, Pérez-Mateo M. Heterogeneity of paracetamol metabolism in Gilbert’s syndrome. Eur J Drug Metab Pharmacokinet. 1999;24(1):9–13.
   PubMed Web of Science ®Google Scholar
• Sim E, Lack N, Wang CJ, et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology. 2008;254(3):170–183.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916–919.
   PubMed Web of Science ®Google Scholar
• Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e55–e57.
   PubMed Web of Science ®Google Scholar
• Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008 Jun;8(3):186–195.
   PubMed Web of Science ®Google Scholar
• Markova SM, De Marco T, Bendjilali N, et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther. 2013;94(6):678–686.
   PubMed Web of Science ®Google Scholar
• Daly AK, Aithal GP, Leathart JB, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272–281.
   PubMed Web of Science ®Google Scholar
• Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 2012;12(6):499–506.
   PubMed Web of Science ®Google Scholar
• Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology. 2003;37(4):924–930.
   PubMed Web of Science ®Google Scholar
• Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43(6):783–786.
   PubMed Web of Science ®Google Scholar
• Kowalec K, Wright GEB, Drögemöller BI, et al. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat Genet. 2018. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar